{"id":55515,"date":"2023-04-04T18:04:10","date_gmt":"2023-04-04T16:04:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/"},"modified":"2023-04-04T18:04:10","modified_gmt":"2023-04-04T16:04:10","slug":"transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/","title":{"rendered":"Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers"},"content":{"rendered":"
\n

\nWebinar to be held Wednesday, April 19, 2023 at 12:00 pm ET \/ 6:00 pm CET<\/p>\n

<\/a><\/p>\n

STRASBOURG, France–(BUSINESS WIRE)–#HBV<\/a>–Regulatory News:<\/p>\n

\nTRANSGENE (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that it will host a virtual Key Opinion Leader (KOL) event on Wednesday, April 19, 2023 at 12:00 pm ET \/ 6:00 pm CET.<\/b><\/p>\n

\nThe KOL webinar will provide insights on TG4050 from expert medical oncologist Professor Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology) who will also discuss the unmet medical need and outlook on treatment landscape for patients suffering from head and neck cancers. Prof. Ottensmeier\u2019s presentation will be followed by a Q&A session.<\/p>\n

\nIn addition, Transgene\u2019s management team will provide a company update, highlighting new Phase I data presented at AACR on April 18, 2023, confirming the high immunogenicity and promising efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation.<\/p>\n

\nTo register for the event, please click here<\/b><\/a>.<\/p>\n

\nTransgene will also present eight posters and have a booth (#310) at AACR which is taking place in Orlando, Florida, on April 14-19, 2023.<\/p>\n

\n***<\/p>\n

\nAbout Transgene
\n
<\/i><\/b>Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene\u2019s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
\n
The Company\u2019s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses:
\n
TG4050, the first individualized therapeutic vaccine based on the myvac<\/i>\u00ae platform, TG4001 for the treatment of HPV-positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO\u00ae viral backbone.
\n
With Transgene\u2019s myvac<\/i>\u00ae platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac<\/i>\u00ae approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
\n
With its proprietary platform Invir.IO\u00ae, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO\u00ae collaboration with AstraZeneca. Additional information about Transgene is available at: www.transgene.fr<\/a>
Follow us on Twitter: @TransgeneSA<\/a><\/p>\n

\nDisclaimer
\n
<\/i><\/b>This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company\u2019s activities, perspectives, financial situation, results, regulatory authorities\u2019 agreement with development phases, and development. The Company\u2019s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and\/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company\u2019s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque\u201d) section of the Universal Registration Document, available on the AMF website (http:\/\/www.amf-france.org<\/a>) or on Transgene\u2019s website (www.transgene.fr<\/a>). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.<\/i><\/p>\n

Contacts<\/b> <\/p>\n

\nTransgene:<\/b>
Lucie Larguier<\/b>
Director Corporate Communications & IR
\n
+33 (0)3 88 27 91 04
\n
investorrelations@transgene.fr<\/a><\/p>\n

\nMedia: MEDiSTRAVA Consulting<\/b>
David Dible \/ Sylvie Berrebi \/ George Underwood<\/b>
+44 (0)203 928 6900
\n
transgene@medistrava.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Webinar to be held Wednesday, April 19, 2023 at 12:00 pm ET \/ 6:00 pm CET STRASBOURG, France–(BUSINESS WIRE)–#HBV–Regulatory News: TRANSGENE (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that it will host a virtual Key Opinion Leader (KOL) event on Wednesday, April 19, 2023 at … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55515","6":"format-standard","7":"category-industry"},"yoast_head":"\nTransgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Webinar to be held Wednesday, April 19, 2023 at 12:00 pm ET \/ 6:00 pm CET STRASBOURG, France–(BUSINESS WIRE)–#HBV–Regulatory News: TRANSGENE (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that it will host a virtual Key Opinion Leader (KOL) event on Wednesday, April 19, 2023 at ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-04T16:04:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230404005860\/en\/1192643\/21\/Logo_Transgene.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers\",\"datePublished\":\"2023-04-04T16:04:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\\\/\"},\"wordCount\":624,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230404005860\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\\\/\",\"name\":\"Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230404005860\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"datePublished\":\"2023-04-04T16:04:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230404005860\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230404005860\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/","og_locale":"en_US","og_type":"article","og_title":"Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers - Pharma Trend","og_description":"Webinar to be held Wednesday, April 19, 2023 at 12:00 pm ET \/ 6:00 pm CET STRASBOURG, France–(BUSINESS WIRE)–#HBV–Regulatory News: TRANSGENE (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that it will host a virtual Key Opinion Leader (KOL) event on Wednesday, April 19, 2023 at ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-04T16:04:10+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230404005860\/en\/1192643\/21\/Logo_Transgene.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers","datePublished":"2023-04-04T16:04:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/"},"wordCount":624,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230404005860\/en\/1192643\/21\/Logo_Transgene.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/","url":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/","name":"Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230404005860\/en\/1192643\/21\/Logo_Transgene.jpg","datePublished":"2023-04-04T16:04:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230404005860\/en\/1192643\/21\/Logo_Transgene.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230404005860\/en\/1192643\/21\/Logo_Transgene.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/transgene-to-host-kol-webinar-on-tg4050-an-individualized-cancer-vaccine-for-the-treatment-of-hpv-negative-head-neck-cancers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55515"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55515\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}